An investigation into the medical and lived experiences of people with recently acquired HIV in Europe and Canada.
HIV IN THE CURRENT DAY
Antiretroviral therapies (ART) and pre-exposure prophylaxis (PrEP) have been revolutionary in the fight against HIV. Despite this, in 2019 an estimated 21,793 people were newly diagnosed with HIV in Western-Europe.
An understanding of the circumstances around contracting HIV is crucial to elimination efforts.
The CASCADE study aims to understand the experiences and needs behind the use or disuse of prevention methods, including PrEP, from the people who are most affected.
With better research and understanding we hope to impact HIV health strategies
to better serve key populations.
Understanding the experience and needs of individuals with newly-acquired HIV
The CASCADE study is a multi-centre study funded through grants from; ViiV Healthcare UK, Janssen Pharmaceutica NV and Merck Sharp & Dohme Corporation.